NYSEMKT: OSTXOs Therapies Inc Stock
$2.40+0.21 (+9.59%)
Updated Aug 21, 2025
OSTX Price
$2.40
Fair Value Price
N/A
Market Cap
$76.54M
52 Week Low
$1.12
52 Week High
$7.00
P/E
-3.04x
P/B
15.48x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$14.28M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.72
Operating Cash Flow
-$12M
Beta
0.77
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OSTX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
OSTX
Ranked#460 of 482
Ranked#460 of 482
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.66 | A | |
| $41.99 | A | |
| $12.08 | A |
Be the first to know about important OSTX news, forecast changes, insider trades & much more!
OSTX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OSTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OSTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OSTX is poor value based on its book value relative to its share price (15.48x), compared to the US Biotechnology industry average (4.56x)
P/B vs Industry Valuation
OSTX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more OSTX due diligence checks available for Premium users.
Valuation
OSTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.04x
Industry
-113.73x
Market
34.76x
OSTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
15.48x
Industry
4.56x
OSTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OSTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.5M
Profit Margin
0%
OSTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.3M
Liabilities
$3.6M
Debt to equity
0.72
OSTX's short-term assets ($3.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OSTX's short-term assets ($3.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OSTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.4M
Investing
-$292.8k
Financing
$2.5M
OSTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OSTX vs Biotech Stocks
Os Therapies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.